WA
RARE icon

WPG Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

WPG Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367 Hold
11
– – ﹤0.01% 1465
2026
Q1 		$230 Hold
11
– – ﹤0.01% 1424
2025
Q4 		$253 Hold
11
– – ﹤0.01% 1433
2025
Q3 		$331 Sell
11
-41
-79% -$1.23K ﹤0.01% 1401
2025
Q2 		$1.89K Hold
52
– – ﹤0.01% 1130
2025
Q1 		$1.88K Sell
52
-36
-41% -$1.5K ﹤0.01% 1129
2024
Q4 		$3.7K Buy
+88
New +$4.37K ﹤0.01% 908

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

WPG Advisers's RARE Position: Q2 2026 in Review

WPG Advisers held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 11 shares worth $367. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

WPG Advisers first reported a position in RARE in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.7K in Q4 2024. 99 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • WPG Advisers held 11 shares of Ultragenyx Pharmaceutical worth $367 as of Q2 2026.
  • WPG Advisers left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1465 holding.
  • WPG Advisers first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • WPG Advisers's Ultragenyx Pharmaceutical position peaked at $3.7K in Q4 2024.
  • 99 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.